Immunomedics Announces 4 Presentations on Epratuzumab at 2013 American College of Rheumatology Annual Meeting

        Print
| Source: Immunomedics, Inc.

MORRIS PLAINS, N.J., Oct. 25, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that 4 presentations on studies of epratuzumab in systemic lupus erythematosus (SLE) will be presented at the 2013 Annual Meeting of the American College of Rheumatology (ACR) to be held in San Diego, CA, from October 26 – 30, 2013.

Epratuzumab is an investigational medicine in development for the treatment of SLE. It is the first monoclonal antibody targeting CD22, a B-cell-specific protein that regulates B-cell activity.1,2 Epratuzumab has not been approved in SLE.

Following is a guide to the investigational studies of epratuzumab for SLE being presented as oral presentations or posters at ACR.

1. Overview Of The Safety Of Epratuzumab In Systemic Lupus Erythematosus
  o  Abstract: #1606
  o  Presenter: Daniel J. Wallace, MD
  o  Date/Time: Monday, October 28, 2013; 8:30 am – 4:00 pm
  o  Location: Exhibit Hall B2-C-D
  o  Session Title: Systemic Lupus Erythematosus – Clinical Aspects II: Central Nervous System Manifestations, Therapeutics
  o  Type: Poster 

2.
 
Epratuzumab Maintains Improvements In Disease Activity For Over 2 Years In Patients With Moderate-To-Severe Systemic Lupus Erythematosus: Results From An Open-Label Long-Term Extension Study
  o  Abstract: #1738
  o  Presenter: Megan E. B. Clowse, MD
  o  Date/Time: Monday, October 28, 2013; 2:30 pm
  o  Location: 33A
  o  Session Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment: Biologic Therapy
  o  Type: Oral 
   
3.
 
Sustained British Isles Lupus Assessment Group-Measured Improvement In Moderately-and-Severely Affected Body Systems In Patients With Systemic Lupus Erythematosus By Epratuzumab: Results From An Open-Label Extension Study
  o  Abstract: #1739
  o  Presenter: Kenneth Kalunian, MD
  o  Date/Time: Monday, October 28, 2013; 2:45 pm
  o  Location: 33A
  o  Session Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment: Biologic Therapy
  o  Type: Oral 
   
4.
 
Sustained Improvements In Health-Related Quality Of Life In Patients With Systemic Lupus Erythematosus Following Epratuzumab Treatment: Results From A Phase IIb Trial And Its Open-Label Extension
  o  Abstract: #2530
  o  Presenter: Vibeke Strand, MD
  o  Date/Time: Tuesday, October 29, 2013; 8:30 am – 4:00 pm
  o  Location: Exhibit Hall B2-C-D
  o  Session Title: Systemic Lupus Erythematosus – Clinical Aspects III: Biomarkers, Quality of Life and Disease Indicators, Late Complications
  o  Type: Poster 
   
References
  1.   Sanz I., Eun-Hyung Lee F. B cells as therapeutic targets in SLE. Rheumatology; Vol. 6. 2010; Pp 326-327.
  2.   Walker J., Smith K. B cells as therapeutic targets in SLE. Immunology; Vol. 123. 2008; Pp 314-325.

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. Our lead product candidate, epratuzumab, is currently in two Phase III clinical trials in lupus. In oncology, we are planning to launch a Phase III pivotal trial for clivatuzumab labeled with a radioisotope in advanced pancreatic cancer patients. Other solid tumor therapeutics in Phase II clinical development include 2 antibody-drug conjugates, labetuzumab-SN-38 (IMMU-130) and hRS7-SN-38 (IMMU-132). We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel DOCK-AND-LOCK™ (DNL™) method with us for making fusion proteins and multifunctional antibodies. DNL™ is being used particularly to make bispecific antibodies targeting cancers and infectious diseases as a T-cell redirecting immunotherapy, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies. We believe that our portfolio of intellectual property, which includes approximately 231 active patents in the United States and more than 400 foreign patents, protects our product candidates and technologies. Our strength in intellectual property has resulted in the top-10 ranking in the 2012 IEEE Spectrum Patent Power Scorecards in the Biotechnology and Pharmaceuticals category. For additional information on us, please visit our website at www.immunomedics.com. The information on our website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with any cash payment that the Company might receive in connection with a sublicense involving a third party and UCB, which is not within the Company's control, new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on UCB for the further development of epratuzumab for non-cancer indications, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

Dr. Chau Cheng
Senior Director, Investor Relations & Grant Management
(973) 605-8200, extension 123